WEKO3
アイテム
Characterization and stabilization of a new 64Cu-labeled anti-EGFR antibody NCAB001 for the early detection of pancreatic cancer with positron emission tomography
https://repo.qst.go.jp/records/85108
https://repo.qst.go.jp/records/851080bf0683f-4a5b-4886-bc6a-838f4d4f2118
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2021-12-28 | |||||
| タイトル | ||||||
| タイトル | Characterization and stabilization of a new 64Cu-labeled anti-EGFR antibody NCAB001 for the early detection of pancreatic cancer with positron emission tomography | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Hiroki, Matsumoto
× Hiroki, Matsumoto× Chika, Igarashi× Tomoko, Tachibana× Fukiko, Hihara× Atsuo, Waki× Zhang, Ming-Rong× Sei, Yoshida× Kenichiro, Naito× Hiroaki, Kurihara× Makoto, Ueno× Kimiteru, Ito× Tatsuya, Higashi× Yukie, Yoshii× Hiroki, Matsumoto× Chika, Igarashi× Tomoko, Tachibana× Fukiko, Hihara× Atsuo, Waki× Zhang, Ming-Rong× Tatsuya, Higashi× Yukie, Yoshii |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Objectives: Early diagnosis of pancreatic cancer using current imaging modalities remains challenging. We have developed a new approach to identify the tumor lesions ≥ 3 mm in the pancreas by positron emission tomography (PET) with intraperitoneally administered 64Cu-labeled new anti-epidermal growth factor receptor (EGFR) antibody (encoded as NCAB001), called 64Cu-NCAB001 ipPET. Generally, in clinical research, radiometal-antibody complex must be prepared immediately before use at imaging site. To make 64Cu-NCAB001 ipPET become available to daily clinical practices sustainably, the NCAB001-chelator conjugate and 64Cu-NCAB001 must be characterized and stabilized. Methods: NCAB001 was manufactured under cGMP conditions. The conjugation of NCAB001 with bifunctional chelator (p-SCN-Bn-PCTA) was conducted, and the antibody-chelator conjugate (PCTA-NCAB001) was characterized by LC/MS and ELISA. Thereafter, to manufacture 64Cu-NCAB001 effectively, we developed a new formulation to stabilize the PCTA-NCAB001 and 64Cu-NCAB001. Results. An average of three PCTA chelators were conjugated per molecule of NCAB001. The relative binding potency of PCTA-NCAB001 was comparable to cetuximab. The formulation consisting of acetate buffer, glycine, and polysorbate-80 stabilized the PCTA-NCAB001 for a year-long storage. Additionally, this formulation enabled the stabilization of 64Cu-NCAB001 for up to 24 h after radiolabeling with sufficient radioactivity concentration for clinical use. Conclusion: These results may accelerate the future use of 64Cu-NCAB001 ipPET in the clinical settings for the early diagnosis and treatment of pancreatic cancer. | |||||
| 書誌情報 |
Pharmaceutics 巻 14, 号 1, p. 67, 発行日 2022-01 |
|||||
| 出版者 | ||||||
| 出版者 | MDPI | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 1999-4923 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.3390/pharmaceutics14010067 | |||||
| 関連サイト | ||||||
| 識別子タイプ | URI | |||||
| 関連識別子 | https://www.mdpi.com/1999-4923/14/1/67 | |||||
